Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

@article{Mascola1996ImmunizationWE,
  title={Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.},
  author={John R. Mascola and Stuart W. Snyder and Owen S. Weislow and S M Belay and Robert B Belshe and David H. Schwartz and Mary Lou Clements and Raphael Dolin and Barney S. Graham and Geoffrey J Gorse and Michael C. Keefer and M. Juliana McElrath and Mary Clare Walker and Kenneth F. Wagner and John G. McNeil and Francine E. McCutchan and Donald S. Burke},
  journal={The Journal of infectious diseases},
  year={1996},
  volume={173 2},
  pages={
          340-8
        }
}
Phase I studies of volunteers not infected with human immunodeficiency virus type 1 (HIV-1) have shown that immunization with envelope subunit vaccine products elicits antibodies that neutralize laboratory-adapted (prototype) HIV-1 strains in vitro. Prototype strains are adapted to grow in continuous (neoplastic) cell lines and are more susceptible to neutralization than are primary isolates cultured in human peripheral blood mononuclear cells. In this study, 50 sera from nine phase I vaccine… Expand
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.
TLDR
It is demonstrated that certain candidate AIDS vaccines can elicit antibodies that neutralize a primary isolate of HIV-1, which is closely related in portions of its envelope to the immunizing strains. Expand
The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases.
TLDR
Sera from vaccinated volunteers are tested against six clade B primary HIV-1 isolates and single isolates of clades C and F and suggest that the sera from vaccinating volunteers have subtype-specific neutralizing antibodies against primaryAIDS isolates, which are more resistant to antibody mediated neutralization compared with laboratory isolates. Expand
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
TLDR
It is concluded that MN rgp120 HIV-1 vaccine was an effective inducer of antibody to native envelope glycoproteins of antigenically diverse primary isolates of HIV- 1. Expand
Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.
TLDR
Assessment conditions for detecting neutralization of primary HIV-1 isolates with sera from immunized individuals are determined and it is recommended that neutralization assays with extended incubation phases should be used to monitor Phase III efficacy trials. Expand
Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection.
TLDR
Sera from vaccine recipients bound to HIV-1-infected cells, but at levels lower than did infected patient sera, and anti-gp120 neutralizing antibodies including human monoclonal antibody 2G12 and goat polyclonal anti-serum to V3 loop peptide [peptide T1-SP10MN(A)] bound toAIDS. Expand
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
TLDR
There is an urgent need to establish standard panels of HIV-1 reference strains for wide distribution and a lack of uniformity in target strains used by different investigators to assess cross-neutralization has made the comparison of vaccine-induced antibody responses difficult. Expand
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160
TLDR
The capacity of a soluble HIV-1 envelope glycoprotein vaccine to elicit an antibody response capable of neutralizing primary HIV- 1 isolates is demonstrated. Expand
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
TLDR
The results support the idea that trimeric gp140 is an improved immunogen compared to monomeric gp120 but that additional improvements are required to afford broad protection against a spectrum of heterologous primary HIV-1 isolates. Expand
Neutralizing Antibodies in Sera from Macaques Infected with Chimeric Simian-Human Immunodeficiency Virus Containing the Envelope Glycoproteins of either a Laboratory-Adapted Variant or a Primary Isolate of Human Immunodeficiency Virus Type 1
TLDR
These results demonstrate that SHIV-HXB2, SHiv-89.6, and SHIV.6P possess highly divergent, strain-specific neutralization epitopes, and provide insights into the requirements for raising neutralizing antibodies to primary isolates of HIV-1. Expand
Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques
TLDR
The results demonstrate the feasibility of generating neutralizing antibodies and cellular immune responses that target an R5 primary HIV-1 isolate by vaccination in primates. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 71 REFERENCES
Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults
TLDR
The combination of live recombinant vaccinia followed by subunit booster immunization was more immunogenic than either product alone and represents a promising approach for HIV-1 immunoprophylaxis. Expand
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
TLDR
The mechanism of resistance of primary isolates to most neutralizing antibodies is complex, and it is suggested that it involves an inaccessibility of antibody binding sites in the context of the native glycoprotein complex on the virion. Expand
Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
TLDR
The safety and immunogenicity of escalating doses of recombinant gp160, a candidate HIV-1 vaccine, were evaluated in 138 HIV-negative volunteers and it was found that rgp160 is a safe and immunogenic candidate HIV vaccine. Expand
Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
TLDR
Although the anti-gp160 antibody response was of similar magnitude in both infected and vaccinated individuals, there were important qualitative differences. Expand
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
TLDR
Sera evaluated for functional serum antibodies and their epitopes suggest that a vaccine that elicits strong serum antibody responses to both regions of gp120 may improve the potential for inducing protective immunity. Expand
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
TLDR
It is found that both low-passage clinical isolates and laboratory-adapted strains of HIV-1 have different sensitivities to neutralization by the same antiserum, depending on the host cell in which the viral stock is prepared. Expand
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
TLDR
It is demonstrated that recombinant gp120, formulated in an adjuvant approved for human use, can elicit protective immunity against a homologous strain of HIV-1. Expand
Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
TLDR
The kinetics of appearance and specificity of HIV-1 neutralizing antibodies was studied in four individuals, and it is likely that the emergence of virus variants which the patient fails to neutralize in the long run contributes to disease progression. Expand
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
  • M. Girard, M. Kieny, +7 authors E. Muchmore
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1991
TLDR
Sustained high titers of neutralizing antibodies were elicited in three chimpanzees after sequential injections of different human immunodeficiency virus 1 (HIV-1) antigen preparations derived from the HIV-1 BRU strain, indicating that it is possible to elicit protection against, or significantly delay infection of, HIV, by immunization, thus laying the foundation for development of an HIV- 1 vaccine. Expand
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
TLDR
The coincidence of changes in neutralization sensitivity with changes in cell tropism and cytopathic effect suggests a common underlying mechanism(s) acting through the whole of the envelope protein complex. Expand
...
1
2
3
4
5
...